SCHEMBL645965

SCHEMBL645965

CSc1ccc(F)c(F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
GAA P10253 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
MCL1 Q07820 1/20 0.38
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
NFE2L2 Q16236 1/20 0.35
MAP2K2 P36507 1/20 0.35
MAP2K1 Q02750 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HTR7 P34969 1/20 0.34
DHFR P00374 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12410552 0.80 MCL1 (0.35) ALDH1A1GAAMCL1MAP2K2MAP2K1
SCHEMBL4899169 0.80 DDB1 (0.35) ALDH1A1GAACYP1A2CYP2C9CYP2C19
SCHEMBL8772911 0.80 MAPT (0.40) ALDH1A1GAACYP1A2CYP2C9CYP2C19
SCHEMBL12410571 0.80 MCL1 (0.35) ALDH1A1GAAMCL1KDM4EMAPT
SCHEMBL4417489 0.80 MAPT (0.40) ALDH1A1GAACYP1A2CYP2C9CYP2C19
SCHEMBL3848854 0.78 MCL1 (0.52) GAAMCL1MAP2K2MAP2K1KDM4E
SCHEMBL15315300 0.78 MCL1 (0.34) ALDH1A1GAACYP1A2MCL1MAP2K2
SCHEMBL387740 0.78 KDM1A (0.37) ALDH1A1GAAMCL1MAP2K2MAP2K1
SCHEMBL29504578 0.78 KDM1A (0.37) ALDH1A1GAAMCL1MAP2K2MAP2K1
SCHEMBL388877 0.78 ALDH1A1 (0.50) ALDH1A1MCL1MAP2K2MAP2K1HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233560-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-07-27 US disclosed
US-20230159564-A1 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers iTeos Belgium SA (BE) 2023-05-25 US disclosed
US-20230159564-A1 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers iTeos Belgium SA (BE) 2023-05-25 US disclosed
US-20230159564-A1 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers iTeos Belgium SA (BE) 2023-05-25 US disclosed
CN-115991679-A 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer 伊忒欧斯比利时股份公司 2023-04-21 CN disclosed
CN-115873022-A 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer 伊忒欧斯比利时股份公司 2023-03-31 CN disclosed
CN-110678472-B 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer 伊忒欧斯比利时股份公司 2023-01-24 CN disclosed
US-20230002387-A1 2-AMINO-S6-SUBSTITUTED THIOPURINE COMPOUNDS AS INHIBITORS OF THE ENPP1 PROTEIN ATEN PORUS LIFESCIENCES PVT. LTD. (IN) 2023-01-05 US disclosed
EP-4112623-A1 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS iTeos Belgium SA (BE) 2023-01-04 EP disclosed
EP-4112623-A1 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS iTeos Belgium SA (BE) 2023-01-04 EP disclosed
US-20050054713-A1 3-Substituted oxindole beta3 agonists JESUDASON CYNTHIA DARSHINI (US) 2005-03-10 US disclosed
US-20040242633-A1 Beta3 adrenergic agonists EVERS BRITTA (DE) 2004-12-02 US disclosed
US-6825220-B2 INVOLVES THE RELATIONSHIP BETWEEN ADRENERGIC RECEPTOR STIMULATION AND ANTI-HYPERGLYCEMIC EFFECTS ELI LILLY AND COMPANY 2004-11-30 US disclosed
US-20040097532-A1 3-Substituted oxindole beta 3 agonists ELI LILLY AND COMPANY 2004-05-20 US disclosed
US-6730792-B2 PYRIDINE DERIVATIVES; ANTIDIABETIC, ANTICHOLESTEROL, AND ANTIINFLAMMATORY AGENTS; DECYCLIZATION, DEETHERIFICATION; OBESITY; RAISES HIGH DENSITY LIPOPROTEINS; LOWERS TRIGLYCERIDE LEVELS ELI LILLY AND COMPANY 2004-05-04 US disclosed
US-20030191156-A1 Beta3 adrenergic agonists JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2003-10-09 US disclosed
EP-0450711-B1 Substituted cyclohexanediones and their herbicidal uses DOWELANCO (US) 1994-07-13 EP disclosed
WO-1991015119-A1 SUBSTITUTED CYCLOHEXANEDIONES AND THEIR HERBICIDAL USES DOWELANCO (US) 1991-10-17 WO disclosed
EP-0450711-A1 Substituted cyclohexanediones and their herbicidal uses DOWELANCO (US) 1991-10-09 EP disclosed
US-5006159-A Oximes, effective against grassy weeds but selective to broadleaf crops such as cotton, sugar beets, soybeans, wheat, rice and corn DOWELANCO (US) 1991-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002387-A1 2-AMINO-S6-SUBSTITUTED THIOPURINE COMPOUNDS AS INHIBITORS OF THE ENPP1 PROTEIN ENPP1, ENPP3, PNP ALDH1A1 3259/4885GAA 1553/4885CYP1A2 3194/4885
US-20030191156-A1 Beta3 adrenergic agonists ADRB3, ADRB1, ADRB2 ALDH1A1 1255/4885GAA 1340/4885CYP1A2 885/4885
US-20050054713-A1 3-Substituted oxindole beta3 agonists ADRB3, ADRB2, ADRB1 ALDH1A1 721/4885GAA 3748/4885CYP1A2 468/4885
US-20040242633-A1 Beta3 adrenergic agonists ADRB3, ADRB1, ADRB2 ALDH1A1 755/4885GAA 1664/4885CYP1A2 761/4885
US-20230233560-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1B, SLC26A4 ALDH1A1 3524/4885GAA 2007/4885CYP1A2 3773/4885
US-20230159564-A1 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers ADORA2A, ADORA2B, ADORA3 ALDH1A1 123/4885GAA 4056/4885CYP1A2 259/4885
US-20040097532-A1 3-Substituted oxindole beta 3 agonists ADRB3, ADRB2, ADRB1 ALDH1A1 520/4885GAA 3402/4885CYP1A2 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.